Why the study?
Pharmacological treatment options for HCM and DCM manage symptoms without addressing disease mechanisms, while directly targeting the sarcomere with small molecules may offer superior therapeutic value.
Small molecules directly targeting the sarcomere, such as myosin modulators, represent a promising therapeutic approach for cardiomyopathies like HCM and DCM.
No takes yet. Share an insight, caveat, or question.
May support myofilament-targeted therapies in HCM/DCM; extends preclinical data into late-phase human trials.
Alsulami et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: